Novel drug-coated balloon

Abstract

A novel drug-coated balloon comprises a balloon and a drug coating coated on the balloon. The drug coating comprises a drug and a drug carrier, the drug is a tissue factor pathway inhibitor which is TFPI-1 or TFPI-2, and the mass ratio of the drug to the drug carrier is 1:(2-3.9). The outer wall of the balloon is provided with the drug coating, and the thickness of the drug coating ranges from 8 micrometers to 15 micrometers. The novel drug-coated balloon has the advantages that the incidence rate of no-reflow phenomenon of PCI postoperation of a patient can be decreased; the incidence rate of stent thrombosis of the patient can be decreased; the reinfarction rate and the fatality rate of the patient are obviously decreased, and long-term prognosis of the patient is improved; the tissue factor pathway inhibitor is a physiological inhibitor of a tissue factor; compared with other drugs, the novel drug-coated balloon has good blood compatibility and tissue compatibility and is free of toxic and side effects and small in influence on a human body.

Description

technical field [0001] The invention relates to a medical balloon, in particular to a drug-coated balloon. Background technique [0002] At present, emergency percutaneous coronary intervention has become the main method of reperfusion treatment for acute myocardial infarction. It can open the infarcted coronary artery as soon as possible, and the area of ​​myocardial necrosis can be reduced accordingly, thereby reducing the mortality rate of patients. However, during the PCI operation, it was found that although the infarcted arteries were opened as soon as possible, the microcirculation often had no-reflow phenomenon, which resulted in the severe hypoxic-ischemic myocardial tissue not receiving effective blood perfusion. The clinical benefits of patients undergoing emergency PCI are greatly reduced, and AMI patients are prone to heart failure, pericardial effusion, and arrhythmia, which increases the mortality rate. [0003] Although the emergence of drug-eluting stents h...

AI Technical Summary

Problems solved by technology

However, during the PCI operation, it was found that although the infarcted arteries were opened as soon as possible, the microcirculation often had no-reflow phenomenon, which resulted in the severe hypoxic-ischemic myocardial tissue not receiving effective blood perfusion. The clinical benefits of patients undergoing emergency PCI are greatly reduced, and AMI patients are prone to heart failure, pericardial effusion, and arrhythmia, which increases the mortality rate

[0003] Although the emergence of drug-eluting stents has greatly reduced the rate of in-stent restenosis, more and more studies have shown that compared with bare metal stents, drug-eluting stents have a higher risk of in-stent thrombosis, resulting in serious adverse clinical consequences

At present, most of the drug-coated stents used clinically are chemical small molecule drugs, which not only inhibit the proliferation of smooth muscle, but also inhibit the growth of endothelial cells, resulting in incomplete endothelialization of the vessel wall and exposure of the cell matrix, thereby promoting the coagulation reaction and increasing The incidence of stent thrombosis, a complication with high infarction rate and mortality

Stent thrombosis after coronary stent implantation has a high rate of re-myocardial infarction and mortality, which brings great harm to patients and society

Images